Obagi Medical Products, Inc. 

(Public, NASDAQ:OMPI)   Watch this stock   
Find more results for OMPI
Jan 14, 2010
OBAGI MEDICAL PRODUCTS INC at JPMorgan Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 12.23% 12.04%
Operating margin 19.78% 19.12%
EBITD margin - 21.33%
Return on average assets 15.57% 19.07%
Return on average equity 18.69% 22.84%
Employees 218 -

Address

310 Golden Shore
Long Beach, CA 90802
United States - Map
+1-562-6281007 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Obagi Medical Products, Inc. discussions

  View all discussions »

Description

Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Officers and directors

Albert J. Fitzgibbons III
Chairman of the Board
Age: 63
Bio & Compensation - Reuters
Steven R. Carlson
President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
Preston S. Romm
Chief Financial Officer, EVP - Finance, Operations and Administration, Treasurer
Bio & Compensation - Reuters
David Goldstein
Executive Vice President - Global Sales and Field Marketing
Bio & Compensation - Reuters
Laura B. Hunter
Vice President, General Counsel, Secretary
Bio & Compensation - Reuters
John A. Bartholdson
Director
Age: 38
Bio & Compensation - Reuters
Edward A. Grant
Director
Age: 59
Bio & Compensation - Reuters
Albert F. Hummel
Director
Age: 64
Bio & Compensation - Reuters
Ronald P. Badie
Director
Age: 66
Bio & Compensation - Reuters
John H. Duerden
Director
Age: 68
Bio & Compensation - Reuters